OncoMatch/Clinical Trials/NCT07100080

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Is NCT07100080 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Iza-bren and Carboplatin for non-small cell lung cancer.

Phase 2/3RecruitingBristol-Myers SquibbNCT07100080Data as of May 2026

Treatment: Iza-bren · Carboplatin · Cisplatin · Pemetrexed — A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Required: EGFR exon 19 deletion

Required: EGFR l858r mutation

Prior therapy

Min 1 prior line

Must have received: third-generation egfr tki (osimertinib, furmonertinib, lazertinib) — adjuvant, locally advanced, or metastatic

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Local Institution - 0279 · Irvine, California
Local Institution - 0154 · Orange, California
Shaw Cancer Center · Edwards, Colorado
Local Institution - 0085 · Gainesville, Florida
Local Institution - 0142 · Pembroke Pines, Florida

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify